How many drugs treat Allergic conjunctivitis?

Drug Landscape tracks 10 marketed treatments for Allergic conjunctivitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/allergic-conjunctivitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Allergic conjunctivitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allergic conjunctivitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Allergic conjunctivitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Loteprednol Etabonate	LOTEPREDNOL	Bausch And Lomb			2020-01-01
Lastacaft	ALCAFTADINE	AbbVie	Histamine-1 Receptor Antagonist [EPC]	Histamine H1 receptor	2010-01-01
Bepreve	BEPOTASTINE	Bausch Health	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
Elestat	EPINASTINE	AbbVie	Adrenergic Receptor Agonist	Histamine H1 receptor	2003-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1998-01-01
Emadine	EMEDASTINE	Novartis	Histamine-1 Receptor Inhibitor	Histamine H1 receptor	1997-01-01
Allegra	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25
Astelin	AZELASTINE	Bayer	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 21 drugs in Allergic conjunctivitis
AbbVie · 5 drugs in Allergic conjunctivitis
Novartis · 5 drugs in Allergic conjunctivitis
Pfizer · 4 drugs in Allergic conjunctivitis
Bayer · 3 drugs in Allergic conjunctivitis
Bausch Health · 2 drugs in Allergic conjunctivitis
Generic (multiple manufacturers) · 2 drugs in Allergic conjunctivitis
GSK · 2 drugs in Allergic conjunctivitis
Bausch And Lomb · 1 drug in Allergic conjunctivitis
Chattem · 1 drug in Allergic conjunctivitis
Auxilium Pharms Inc · 1 drug in Allergic conjunctivitis
Brooke Army Medical Center · 1 drug in Allergic conjunctivitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Allergic conjunctivitis:

Cite this brief

Drug Landscape (2026). Allergic conjunctivitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/allergic-conjunctivitis. Accessed 2026-06-10.

Allergic conjunctivitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing